Adeno-associated virus (AAV) is already gene therapy’s delivery vehicle of choice. And now, more efficient AAVs are being engineered using directed evolution and AI-guided workflows . . .
- Tech Exclusives
- GEN Edge
- Magazine
- September 2019 Vol. 39 No. 9
- Genome Editing
- Gene Therapy
- Insights
- Viral Vectors
Going Viral: The Next Generation of AAV Vectors
Better AAV capsids are being engineered using directed evolution and AI-guided workflows
The technician in this image is working at a Spark Therapeutics facility in Philadelphia, where Spark manufactures its own adeno-associated viral (AAV) vectors. In addition to this facility, Spark has a proprietary platform for AAV vector development. The company indicates that its vectors have been used in more than a dozen trials as well as in Luxterna, Spark’s approved gene therapy product.
